Loading clinical trials...

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

NCT03075644•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This trial is conducted in Asia. The aim of this trial is to evaluate the safety of once weekly dosing of somapacitan (NNC0195-0092) and daily Norditropin® FlexPro® for 52 weeks in previously human growth hormone treated Japanese adults with growth hormone deficiency.

Eligibility

Age

18 - 79 years

Sex

ALL

Healthy Volunteers

No

Locations (12)

Novo Nordisk Investigational Site

Bunkyo-ku, Tokyo, Japan

Novo Nordisk Investigational Site

Chiba-shi, Chiba, Japan

Novo Nordisk Investigational Site

Fukuoka, Japan

Novo Nordisk Investigational Site

Kagoshima, Japan

Novo Nordisk Investigational Site

Kobe, Hyogo, Japan

Novo Nordisk Investigational Site

Kyoto-shi Kyoto, Japan

Novo Nordisk Investigational Site

Okayama, Okayama, Japan

Novo Nordisk Investigational Site

Osaka, Japan

Novo Nordisk Investigational Site

Sagamihara-shi, Kanagawa, Japan

Novo Nordisk Investigational Site

Tokyo, Japan

Key Dates

Start Date

March 3, 2017

Primary Completion Date

October 4, 2018

Completion Date

October 4, 2018

Last Updated

November 23, 2020

Enrollment

62

ACTUAL participants

Conditions

Growth Hormone DisorderAdult Growth Hormone Deficiency

Interventions

somapacitan

DRUG

Norditropin

DRUG

Sponsors

Lead Sponsor

Novo Nordisk A/S

Related Studies

ENROLLING_BY_INVITATION

Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®

NCT05230550

Adult Growth Hormone Deficiency

NOT_YET_RECRUITINGPHASE2

A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

NCT07259564

Adult Growth Hormone Deficiency (AGHD)

COMPLETEDPHASE1

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 23, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions